Talecris Biotherapeutics, the Triangle's largest biotechnology company, held its first ever annual stockholders meeting this morning in Chapel Hill.
About a half dozen attendees, including a lone retiree, turned up to enjoy a spread of croissants, fresh fruit and coffee at the Carolina Inn in Chapel Hill.
Talecris CEO Lawrence Stern interpreted the light crowd as a good sign.
"That it's a small turnout, in my mind, is a good thing, because it shows there are no concerns out there," Stern said after the meeting.
Talecris, which makes medicines from blood plasma at its massive Clayton manufacturing plant, raised $950 million in an initial public offering last fall. The Research Triangle Park company elected two people, Paul N. Clark and Kenneth J. Martin, to its board this morning.
Stern said Talecris has begun initial site work on the expansion of its Clayton plant. In November, the company received a package of tax breaks and other financial aid worth nearly $20 million as part of the expansion, which will create 259 jobs over the next seven years.
The first stage will be a $280 million facility to separate proteins in blood plasma that are used to make medicine. That project will take several years to open, a process that will require approval from the Food and Drug Administration.
Talecris owns one building in RTP and leases office and lab space in three others. The company also leases space on N.C. State's Centennial Campus and operates 69 plasma collection centers.
Stern said this morning that it's logical to assume that Talecris will eventually need additional office space as it continues to grow, but the company has no formal plans at the moment to add new space.